Fig. 1.

Patients with rapid renal disease progression experienced clinical events prior to the initiation of agalsidase beta treatment. Patients were grouped into quartiles (Q), based on eGFR slope. Data are expressed as the percentage of patients within each eGFR slope quartile who had a stroke or cardiovascular event (as defined in Materials and Methods section) prior to the initiation of agalsidase beta treatment. The numbers above each bar indicate number of patients who had clinical events prior to the initiation of treatment/total number of patients in each quartile. Data for males are shown in light grey bars and data for females are shown in dark grey bars.